CTOs on the Move

Allegro Ophthalmics

www.allegroeye.com

 
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.allegroeye.com
  • 31473 Rancho Viejo Road Suite 204
    San Juan Capistrano, CA USA 92675
  • Phone: 949.940.8130

Executives

Name Title Contact Details

Similar Companies

Beech Brook

Helping children & families thrive by promoting healthy child development, strengthening the ability to overcome adversity, & enhancing family health & stability.

Groupe Parima

Groupe Parima is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Challenge Printing Company, The

Challenge Printing Company, The is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gala Design Inc

Gala Design Inc is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerebral

At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient outcomes for years to come. With a heavy focus on clinical quality and safety in all that we do, we`ve accomplished excellent patient outcomes: • 82% of patients report an improvement in their anxiety symptoms after using Cerebral. • 75% of patients who report improvement in their depression see improvement within 60 days. • 50% of patients who initially report suicidal ideation no longer harbor suicidal thoughts after treatment with Cerebral. This is just the beginning for Cerebral, and we won`t stop building, growing, and iterating until everyone, everywhere can access high-quality evidence-based mental health care without high costs and/or long wait times. We`re looking for mission-driven leaders who share these values, and we need your help as we transform access to high-quality mental health care in the United States and beyond.